跳至主要内容
临床试验/CTRI/2024/07/070464
CTRI/2024/07/070464尚未招募Unknown

Prevalence of metabolic syndrome and its risk factors in patients receiving Clozapine therapy for schizophrenia- A prospective observational study - NI

AIIMS Raipur0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. All genders aged between 18 years to 65 years.
  • 2. All patients with Schizophrenia diagnosed as per International Classification of disease 10 (ICD-10).
  • 3. Patients prescribed Clozapine.
  • 4. Medically stable patients.

排除标准

  • 1. Unstable patients i.e. patients with violence, suicide risk, and risk of harm to self/others.
  • 2. Patients with diagnosable intellectual disability.
  • 3. Pregnant or lactating patients.
  • 4. Medically unstable patients.
  • 5. Severely physical disability or locomotive disability.
  • 6. History of substance dependence other than tea or coffee.
  • 7. History of significant weight loss in the past month.
  • 8. Patients on metabolism-friendly medication (Such as Aripiprazole, Brexpiprazole, Lurasidone, Topiramate etc).

研究者

发起方
AIIMS Raipur

相似试验